BenevolentAI
target validation in colon tissue from ulcerative colitis patients in colonic mucosa biopsies from patients disease phenotype retained with high basal release and key mediators of pathology tissue samples treated with target selective tool compound ben positive controls and selective target inhibition showed comparable reduction of and to the positive controls validated as a target with a novel mechanism of action for ulcerative colitis | BenevolentAI
Company
Deck date
October 2022
Slide
22 of 46
Similar slides by BenevolentAI
Results
March 2023
Investor Conference
January 2023
Investor Day
September 2022
Related slides by other companies
Investor Presentation
November 2023
IPO
October 2022
Investor Day
September 2022
Investor Day
December 2023
Other recent decks by BenevolentAI
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io